Secukinumab (Cosentyx) and Ketamine Therapy | Tovani Health
Cosentyx (Secukinumab) — IL-17A monoclonal antibody (psoriasis, psoriatic arthritis, AS)
Verdict at Tovani Health
Fully compatible with KAP.
Secukinumab and ketamine have no clinically significant interaction. Used for moderate-to-severe psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. Same clean biologic profile.
If you take Cosentyx regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Cosentyx interacts with ketamine
Secukinumab is a fully human mAb that neutralizes IL-17A. Subcutaneous injection monthly after loading. No CYP interactions with ketamine.
What we do at intake
Continue as scheduled.
Bottom line
Secukinumab and ketamine have no clinically significant interaction. Used for moderate-to-severe psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. Same clean biologic profile.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Cosentyx (Secukinumab) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 22, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.